BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
(Reuters) — A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc., finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.
The two companies have been embroiled in a case involving accusations that Yescarta, the CAR-T cell cancer immunotherapy from Gilead's Kite Pharma unit, infringed on a patent for a similar therapy from Bristol's Juno Therapeutics.
Last year, a federal judge increased the damages from a jury trial and ordered Gilead to pay Bristol Myers $1.2 billion in the patent infringement case. The ruling on Thursday by the U.S. Court of Appeals for the Federal Circuit reversed the decision.
Bristol Myers in a statement said it disagreed with the latest ruling and would seek a review of the Federal Circuit’s decision.
Gilead and Kite's attorney Josh Rosenkranz of Orrick Herrington & Sutcliffe did not immediately respond to a request for comment.
Gilead shares were up 0.3%, while Bristol shares were off 0.5% in midday trading.
The Gilead drug, Yescarta, belongs to a class of cutting-edge cancer treatments known as chimeric antigen receptor T-cell therapy, or CAR-T, which reprograms the body's own immune cells to recognize and attack malignant cells.
Gilead bought Kite Pharma, which developed Yescarta, for $11.9 billion in 2017, with the treatment securing U.S. approval that year. It recorded sales of $338 million in the first six months of this year.
A jury in 2019 found that Kite willfully infringed and awarded Juno and Memorial Sloan Kettering Cancer Center in New York, which licenses the patent to Juno, $778 million. U.S. District Judge Philip Gutierrez increased the award to $1.2 billion in Los Angeles federal court last year.
Memorial Sloan Kettering did not immediately respond to a request for comment.
Bristol Myers acquired Juno and its CAR-T program with its $74 billion purchase of Celgene in 2019.
Chief U.S. Circuit Judge Kimberly Moore wrote for a unanimous three-judge panel that the relevant parts of Juno’s patent were invalid because they lacked a sufficient written description and details.
Judge Moore was joined by Circuit Judges Sharon Prost and Kathleen O'Malley in the ruling.
During a July oral argument, Judge Moore compared the patent's description to trying to identify a specific car by saying it has four wheels.
(Reuters) — Merck & Co. on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc. over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.